GRIK4: A Potential Drug Target Or Biomarker for Diseases (G2900)

Target Name: GRIK4

NCBI ID: G2900

GRIK4

GRIK4: A Potential Drug Target Or Biomarker for Diseases

GRIK4 (GRIK4 variant 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The GRIK4 gene is located on chromosome 12 and encodes for a protein known as GRIK4, which is a key regulator of microRNA (miRNA) levels in the cell.

Studies have shown that GRIK4 plays a crucial role in the regulation of miRNA levels, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. miRNA levels are regulated by a complex interplay of factors, including GRIK4, which can either activate or inhibit the activity of other proteins that regulate miRNA levels.

One of the key functions of GRIK4 is its ability to interact with the microRNA-binding protein miRNA-consverting enzyme (miRNA-C) to regulate the levels of miRNA in the cell. GRIK4 has been shown to physically interact with miRNA-C and to influence the stability of miRNA, leading to the formation of stable miRNA duplexes that can activate or repress the activity of other miRNAs.

GRIK4 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, GRIK4 has been shown to regulate the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases such as cancer and neurodegenerative disorders.

In addition to its role in the regulation of miRNA levels, GRIK4 has also been shown to play a critical role in the regulation of cellular processes that are important for the development and progression of diseases. For example, GRIK4 has been shown to regulate the production of angiogenic factors, which are factors that promote the formation of new blood vessels and contribute to the development of vascular diseases.

GRIK4 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of diseases. For example, GRIK4 has been shown to regulate the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases such as cancer and neurodegenerative disorders.

GRIK4 has also been shown to play a critical role in the regulation of cellular processes that are important for the development and progression of diseases. For example, GRIK4 has been shown to regulate the production of angiogenic factors, which are factors that promote the formation of new blood vessels and contribute to the development of vascular diseases.

In conclusion, GRIK4 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The GRIK4 gene is located on chromosome 12 and encodes for a protein known as GRIK4, which is a key regulator of microRNA (miRNA) levels in the cell. GRIK4's ability to interact with the microRNA-binding protein miRNA-consverting enzyme (miRNA-C) and to influence the regulation of miRNA levels has been shown to play a crucial role in the development and progression of various diseases. Further research is needed to fully understand the role of GRIK4 in the regulation of miRNA levels and its potential as a drug target or biomarker.

Protein Name: Glutamate Ionotropic Receptor Kainate Type Subunit 4

Functions: Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists

The "GRIK4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRIK4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets